Prima BioMed Ltd. announced that Bradley J. Monk, MD, has joined the company's clinical advisory board to advise the company's development of CVac(TM) for the treatment of epithelial ovarian cancer. Dr. Monk is an active member of steering committees (SC) for the National Cancer Institute (NCI) and Gynecological Oncology Group (GOG).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.44 AUD | 0.00% | -7.37% | +27.54% |
May. 17 | Capital One Initiates Immutep at Overweight Rating With $10 Price Target | MT |
May. 15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.54% | 348M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+36.67% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Bradley J. Monk to Join Prima Biomed's Clinical Advisory Board